Myelodysplastic Syndromes (MDS)
Oncology·MeSH: Myelodysplastic Syndromes
Prevalence
13.0 / 100K
Incidence
4.6 / 100K/yr
5 drugs in development·5 companies·5 clinical trials
Drug Pipeline by Phase
Approved(2)
Phase 3(1)
| Drug | Company |
|---|---|
| luspatercept | CELGENE CORP /DE/ (CELG) |
Phase 2(1)
| Drug | Company |
|---|---|
| Elritercept | Merus N.V. (MRUS) |
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| nkx101 | Nkarta, Inc. (NKTX) |
Compare drugs
Frequently asked questions
How many drugs are in development for Myelodysplastic Syndromes (MDS)?
BioSniper tracks 5 drugs in development for Myelodysplastic Syndromes (MDS) across 5 companies.
How many clinical trials target Myelodysplastic Syndromes (MDS)?
There are 5 clinical trials targeting Myelodysplastic Syndromes (MDS) tracked by BioSniper.
What is the prevalence of Myelodysplastic Syndromes (MDS)?
The estimated prevalence of Myelodysplastic Syndromes (MDS) is approximately 13.0 per 100,000 population.
Deep-dive into Myelodysplastic Syndromes (MDS)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis